Dr. Schenk is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3130 Highland Blvd
Bozeman, MT 59715
Summary
- Dr. Kara Schenk is is a board-certified oncologist at Bozeman Health Deaconess Hospital Cancer Center and adjunct instructor at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. She completed her medical education and residency in Internal Medicine at Johns Hopkins University School of Medicine in 2015 and 2018, respectively. She is known for her multiple publications in the field of oncology. Her research interest is in developing combinatorial immunotherapy regimens for patients with advanced cutaneous malignancies, with a focus on patient populations who might otherwise not be eligible for clinical trials (e.g., solid organ transplant recipients) and patients with rare presentations (e.g., metastatic basal cell carcinoma).
Education & Training
- Johns Hopkins UniversityFellowship, Medical Oncology, 2020 - 2023
- Johns Hopkins UniversityResidency, Internal Medicine, 2015 - 2018
- Johns Hopkins University School of MedicineClass of 2015
Certifications & Licensure
- MD State Medical License 2018 - 2025
- MT State Medical License 2023 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 9 citationsNivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.Kara M Schenk, Julie Stein Deutsch, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu
Journal of Clinical Oncology. 2024-03-20 - 4 citationsImmune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade.Julie Stein Deutsch, Jonathan Lai, Kara M Schenk, Abha Soni, Elizabeth M Will
Journal for Immunotherapy of Cancer. 2023-12-14 - 2 citationsTumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma.Maryam Pourmaleki, Caitlin J Jones, Charlotte E Ariyan, Zheng Zeng, Mono Pirun
Cancer Immunology Research. 2022-03-01
Press Mentions
- Tip Sheet: Johns Hopkins Kimmel Cancer Center Researchers to Present at Asco Annual MeetingMay 26th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: